AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20571361 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.7 degrees +/- 0.5 degrees C)
Number of subjects: 1000
Study 20571361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia
Number of subjects: 1000
Study 20571361 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 1000
Study 18001429 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with fresh cow's milk
Number of subjects: 104
Study 18001429 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with casein
Number of subjects: 104
Study 18001429 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with all three milk proteins (alpha-lactalbumin, casein, beta-lactoglobulin)
Number of subjects: 104
Study 18001429 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with alpha-lactalbumin
Number of subjects: 104
Study 18001429 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with beta-lactoglobulin
Number of subjects: 104
Study 18001429 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenge test
Number of subjects: 104
Study 16339333 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement
Number of subjects: 1084
Study 16339333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study 12000000 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler (budesonide 800 microg day(-1), 200 g dose(-1), two inhalations twice daily for 12 weeks)
Number of subjects: 161
Study 12000000 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler (budesonide 800 microg day(-1), 200 g dose(-1), two inhalations twice daily for 12 weeks)
Number of subjects: 161
Study 12000000 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 161
Study 12000000 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 161
Study 10434872 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal tension glaucoma patients
Number of subjects: 24
Study 10434872 — intervention group
Group type: COMPARATOR
Intervention: Age matched controls
Number of subjects: 24
Study 7763063 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day)
Number of subjects: 41
Study 7763063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2271378 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg (F)
Number of subjects: 12
Study 2271378 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg in combination with triamterene 50 mg (F+T)
Number of subjects: 12
Study 6986552 — intervention group
Group type: EXPERIMENTAL
Intervention: Leboyer method of delivery
Number of subjects: 56
Study 6986552 — intervention group
Group type: COMPARATOR
Intervention: Conventional delivery
Number of subjects: 56
Study 29723066 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based patient education (WBPE) with action and coping plans
Number of subjects: 108
Study 29723066 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (web-based neutral information program about shoulder injuries)
Number of subjects: 108
Study 28282219 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 2
Study 25832102 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MenC-CRM dose at 3 months
Number of subjects: 509
Study 25832102 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of MenC-CRM at 3 and 4 months
Number of subjects: 509
Study 25832102 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MenC-polysaccharide-TT dose at 3 months
Number of subjects: 509
Study 25832102 — intervention group
Group type: COMPARATOR
Intervention: No MenC doses
Number of subjects: 509
Study 22457418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion (LPD) group received 100 mL of a 20% soybean oil emulsion for 7 days after esophagectomy.
Number of subjects: 32
Study 22457418 — intervention group
Group type: COMPARATOR
Intervention: Control group received parenteral feeding with a glucose-based solution only.
Number of subjects: 32
Study 22457418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion (LPD) group
Number of subjects: 32
Study 22457418 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 21889410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 660
Study 21889410 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 660
Study 19183929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cycle of BEP (bleomycin, etoposid, cisplatin)
Number of subjects: 382
Study 19183929 — intervention group
Group type: COMPARATOR
Intervention: RPLND (retroperitoneal lymphadenectomy)
Number of subjects: 382
Study 17284127 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day of aripiprazole
Number of subjects: 83
Study 17284127 — intervention group
Group type: COMPARATOR
Intervention: 6 mg/day of risperidone
Number of subjects: 83
Study 15011838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative needle decompression of the colon (n=23)
Number of subjects: 50
Study 15011838 — intervention group
Group type: COMPARATOR
Intervention: Non-decompression (n=27)
Number of subjects: 50
Study 15011838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (decompression and non-decompression)
Number of subjects: 50
Study 11706963 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous migraine aura patients
Number of subjects: 18
Study 11706963 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually induced migraine aura patients
Number of subjects: 18
Study 11706963 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 18
Study 9254274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined laser-ultraviolet irradiation
Number of subjects: 0
Study 8432572 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw
Number of subjects: 100
Study 8432572 — intervention group
Group type: COMPARATOR
Intervention: McLaughlin nail‐plate
Number of subjects: 100
Study 3497780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tiaprofenic acid 600 mg once daily
Number of subjects: 485
Study 3497780 — intervention group
Group type: COMPARATOR
Intervention: Standard tiaprofenic acid 300 mg tablets twice daily
Number of subjects: 485
Study 3497780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 485
Study 30688793 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Number of subjects: 45
Study 30688793 — intervention group
Group type: COMPARATOR
Intervention: Center-based pulmonary rehabilitation
Number of subjects: 45
Study 28699544 — intervention group
Group type: EXPERIMENTAL
Intervention: Camino Verde intervention
Number of subjects: 0
Study 28699544 — intervention group
Group type: COMPARATOR
Intervention: Regular water supply
Number of subjects: 0
Study 26139105 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified paleolithic diet
Number of subjects: 20
Study 26139105 — intervention group
Group type: COMPARATOR
Intervention: Standard diet adhering to the Nordic Nutrition Recommendations
Number of subjects: 20
Study 24135553 — intervention group
Group type: EXPERIMENTAL
Intervention: Open‐Monitoring meditation
Number of subjects: 3
Study 24135553 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Attention meditation
Number of subjects: 3
Study 24135553 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 3
Study 22009540 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide (Ultravist™, Bayer Health Care)
Number of subjects: 200
Study 22009540 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol (Visipaque™, Nycomed Amersham)
Number of subjects: 200
Study 18205247 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation-based strategies for handling intermittent missing values and dropouts
Number of subjects: 0
Study 18205247 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple partial imputation
Number of subjects: 0
Study 16510063 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 selective NSAIDs
Number of subjects: 0
Study 16510063 — intervention group
Group type: COMPARATOR
Intervention: Nonselective NSAIDs
Number of subjects: 0
Study 15535881 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated lumbar extensor training (10-week program, 2 sessions per week, 10-15 minutes each)
Number of subjects: 0
Study 15535881 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated lumbar extensor training
Number of subjects: 0
Study 15535881 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 11195718 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective frequency rating
Number of subjects: 1916
Study 11195718 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rating
Number of subjects: 1916
Study 11195718 — intervention group
Group type: EXPERIMENTAL
Intervention: Interjudge reliability
Number of subjects: 1916
Study 11195718 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between subjective frequency and imagery
Number of subjects: 1916
Study 11195718 — intervention group
Group type: EXPERIMENTAL
Intervention: Validity estimates
Number of subjects: 1916
Study 9308933 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy with endoscopic dilatation/intubation (Group 1a)
Number of subjects: 104
Study 9308933 — intervention group
Group type: COMPARATOR
Intervention: Natural course of the disease with palliation (Group 1b)
Number of subjects: 104
Study 9308933 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with endoscopic intubation (Group 2a)
Number of subjects: 104
Study 9308933 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic intubation alone (Group 2b)
Number of subjects: 104
Study 8370487 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposuspension according to Burch
Number of subjects: 52
Study 8370487 — intervention group
Group type: EXPERIMENTAL
Intervention: Suburethral sling procedure
Number of subjects: 52
Study 3548295 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 10
Study 3548295 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 10
Study 3548295 — intervention group
Group type: COMPARATOR
Intervention: pre drug control
Number of subjects: 10
Study 30328956 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 300 mg
Number of subjects: 57
Study 30328956 — intervention group
Group type: COMPARATOR
Intervention: CBD 150 mg
Number of subjects: 57
Study 30328956 — intervention group
Group type: COMPARATOR
Intervention: CBD 600 mg
Number of subjects: 57
Study 30328956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 28517367 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP)
Number of subjects: 506
Study 28517367 — intervention group
Group type: COMPARATOR
Intervention: Standard biventricular (Bi-V) pacing
Number of subjects: 506
Study 28517367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MPP and Bi-V pacing
Number of subjects: 506
Study 25469520 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced personal contact with patients across time coupled with basic HIV education
Number of subjects: 1228
Study 25469520 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 1228
Study 23408048 — intervention group
Group type: EXPERIMENTAL
Intervention: NavX-guided slow pathway ablation
Number of subjects: 42
Study 23408048 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided slow pathway ablation
Number of subjects: 42
Study 21247247 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (up to 12 mg/day)
Number of subjects: 201
Study 21247247 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (up to 10 mg/day)
Number of subjects: 201
Study 21247247 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan and Amlodipine
Number of subjects: 201
Study 19409533 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 16
Study 19409533 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) injection
Number of subjects: 16
Study 17701889 — intervention group
Group type: EXPERIMENTAL
Intervention: NN414 1.5 mg/kg
Number of subjects: 24
Study 17701889 — intervention group
Group type: EXPERIMENTAL
Intervention: NN414 4.5 mg/kg
Number of subjects: 24
Study 17701889 — intervention group
Group type: EXPERIMENTAL
Intervention: NN414 10 mg/kg
Number of subjects: 24
Study 17701889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17701889 — intervention group
Group type: EXPERIMENTAL
Intervention: NN414 (1.5, 4.5, and 10 mg/kg)
Number of subjects: 24
Study 15023486 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy intervention
Number of subjects: 268
Study 15023486 — intervention group
Group type: COMPARATOR
Intervention: Baby-play control
Number of subjects: 268
Study 15023486 — intervention group
Group type: COMPARATOR
Intervention: Usual service control
Number of subjects: 268
Study 11727838 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Methotrexate (7.5 mg/week) combined with Naproxen (1000 mg/day)
Number of subjects: 51
Study 11727838 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (1000 mg/day) alone
Number of subjects: 51
Study 9859964 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (3 g of the 20% liquid solution) 1 hour before each dose of TMP-SMX (trimethoprim 80 mg, sulfamethoxazole 400 mg) twice daily
Number of subjects: 238
Study 9859964 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX alone
Number of subjects: 238
Study 7626569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl methylcellulose (Ocucoat)
Number of subjects: 0
Study 7626569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healonid)
Number of subjects: 0
Study 2681559 — intervention group
Group type: EXPERIMENTAL
Intervention: 4x1 g ampicillin intravenously over 3 days
Number of subjects: 60
Study 2681559 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 60
Study 847691 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestagens (Chlormadinone acetate 2 mgx2, Medroxyprogesteroneacetate 5 mgx2, Norethisterone 5 mgx2)
Number of subjects: 100
Study 847691 — intervention group
Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 100
Study 30886326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/day for 3 weeks)
Number of subjects: 16
Study 31391698 — intervention group
Group type: EXPERIMENTAL
Intervention: Visudrop (coenzyme Q + vitamin E + hypermellosis) applied during surgery and postoperatively
Number of subjects: 32
Study 31391698 — intervention group
Group type: COMPARATOR
Intervention: Routine FAKO + IOL implantation surgery (Control Group)
Number of subjects: 32
Study 28960033 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9601 (3 times daily for 2 weeks)
Number of subjects: 434
Study 28960033 — intervention group
Group type: COMPARATOR
Intervention: DA-5204 (twice daily for 2 weeks)
Number of subjects: 434
Study 26053217 — intervention group
Group type: EXPERIMENTAL
Intervention: STN stimulation ON
Number of subjects: 16
Study 26053217 — intervention group
Group type: COMPARATOR
Intervention: STN stimulation OFF
Number of subjects: 16
Study 23683286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic technique for removing fractured rotary files
Number of subjects: 70
Study 21552071 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic Memory and Reasoning Training (SMART)
Number of subjects: 28
Study 21552071 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Workshop (BHW)
Number of subjects: 28
Study 21552071 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 28
Study 19631319 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA 19-9
Number of subjects: 179
Study 19631319 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 125
Number of subjects: 179
Study 19631319 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 and CA 125 combined
Number of subjects: 179
Study 17370485 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Shaoze (SI 1)
Number of subjects: 276
Study 17370485 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) at Shangyang (LI 1)
Number of subjects: 276
Study 15286123 — intervention group
Group type: EXPERIMENTAL
Intervention: New clinical trial methodology for caries studies
Number of subjects: 0
Study 15286123 — intervention group
Group type: COMPARATOR
Intervention: Conventional two‐ to three‐year caries studies
Number of subjects: 0
Study 11789552 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 150
Study 11789552 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 150
Study 10168895 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation and aspirin treatment
Number of subjects: 0
Study 10168895 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum lipid levels
Number of subjects: 0
Study 10168895 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 7942488 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (early mitral closure)
Number of subjects: 20
Study 3076995 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed Mycobacterium leprae added to BCG vaccination
Number of subjects: 0
Study 3076995 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeating BCG vaccination
Number of subjects: 0
Study 3076995 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination alone
Number of subjects: 0
Study 31423955 — intervention group
Group type: EXPERIMENTAL
Intervention: General dysfunctional beliefs measured by the Dysfunctional Attitude Scale (DAS)
Number of subjects: 118
Study 31423955 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific illness beliefs measured by the Illness Perceptions Questionnaire‐Revised (IPQ‐R)
Number of subjects: 118
Study 31423955 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 118
Study 31423955 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorders assessed by the Structured Clinical Interview for DSM‐IV Axis‐I Disorders (SCID‐I)
Number of subjects: 118
Study 30919236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck extension
Number of subjects: 121
Study 30919236 — intervention group
Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 121
Study 27397060 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus vildagliptin 100 mg (InsV)
Number of subjects: 32
Study 27397060 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (Ins)
Number of subjects: 32
Study 25418987 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase (Oncaspar®) 1,000 IU/m²/dose administered intramuscularly at 2 or 6 weeks intervals for a total of 30 weeks
Number of subjects: 615
Study 25418987 — intervention group
Group type: COMPARATOR
Intervention: Erwinase therapy
Number of subjects: 615
Study 23403950 — intervention group
Group type: EXPERIMENTAL
Intervention: DES with a biodegradable polymer (n=50)
Number of subjects: 100
Study 23403950 — intervention group
Group type: COMPARATOR
Intervention: DES with a permanent polymer (n=50)
Number of subjects: 100
Study 21691606 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched configuration (narrower replaceable components)
Number of subjects: 26
Study 21691606 — intervention group
Group type: COMPARATOR
Intervention: Original protocol (control group)
Number of subjects: 26
Study 19105270 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese traditional medicine (oral administration)
Number of subjects: 60
Study 19105270 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib and glucosamine hydrochloride (oral administration)
Number of subjects: 60
Study 17449992 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like electrical stimulation
Number of subjects: 36
Study 17449992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham stimulator)
Number of subjects: 36
Study 15472639 — intervention group
Group type: EXPERIMENTAL
Intervention: gated FDG PET imaging
Number of subjects: 90
Study 11566625 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SLE
Number of subjects: 60
Study 11566625 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF
Number of subjects: 60
Study 11566625 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF
Number of subjects: 60
Study 11566625 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐beta1
Number of subjects: 60
Study 11284464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 1831
Study 11284464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 1831
Study 11284464 — intervention group
Group type: COMPARATOR
Intervention: Standard care medications
Number of subjects: 1831
Study 7870724 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide methods (infusion dynamic ureteroscintigraphy, dynamic and static scintigraphy of the kidneys, radionuclide renography)
Number of subjects: 246
Study 7870724 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide methods
Number of subjects: 246
Study 7870724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive radionuclide techniques
Number of subjects: 246
Study 7870724 — intervention group
Group type: COMPARATOR
Intervention: Control group (51 patients)
Number of subjects: 246
Study 12316112 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 200
Number of subjects: 300
Study 12316112 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload Copper 250
Number of subjects: 300
Study 12316112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippes Loop C
Number of subjects: 300
Study 28795605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 0
Study 28795605 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reduction intervention
Number of subjects: 0
Study 28795605 — intervention group
Group type: COMPARATOR
Intervention: Repeated exposure to sugar-free coffee (Control)
Number of subjects: 0
Study 30423130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency vibration device for 20 minutes per day (Group B)
Number of subjects: 45
Study 30423130 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (Group A)
Number of subjects: 45